Source: Markets Insider

Berkery Noyes: Eliaz Therapeutics is Raising Capital to Develop its Therapeutic Apheresis Device to Treat Acute Kidney Injury

NEW YORK, Oct. 12, 2021 /PRNewswire/ -- Berkery Noyes Securities is pleased to announce it has been retained by Eliaz Therapeutics ('ETI'), develo...

Read full article »
Berkery Noyes's Competitors | Berkery Noyes's News | Berkery Noyes's Financials
Stay up-to-date with the latest news on Berkery Noyes
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Joseph W. Berkery's photo - President & CEO of Berkery Noyes

President & CEO

Joseph W. Berkery

CEO Approval Rating

89/100

Read more
Stay up-to-date with the latest news on Berkery Noyes